Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

REVIEW ARTICLE

Dosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol—Practical Experience

Christiane Schuchardt, Harshad Kulkarni, Carolin Zachert, Richard P Baum

Citation Information : Schuchardt C, Kulkarni H, Zachert C, Baum RP. Dosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol—Practical Experience. J Postgrad Med Edu Res 2013; 47 (1):65-73.

DOI: 10.5005/jp-journals-10028-1058

Published Online: 00-03-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

Calculating the absorbed dose is important for the determination of risk and therapeutic benefit of internal radiation therapy. Optimal dose estimations require time-consuming and sophisticated methods, which are difficult due to practical reasons. To make dosimetry available for each of the patients, we developed a specific dosimetry procedure used in daily clinical routine.

Materials and methods

Dosimetry has been performed according to the MIRD scheme and adapted to the special conditions at our department (which we have called as the Bad Berka Dose protocol, BBDP): Conjugated planar whole-body scintigraphies at 0.5, 3, 24, 48 and 72 hours postinjection are analyzed by regions of interest with ‘HERMES WHOLE-BODY DISPLAY’ and the time-dependent organ and tumor activities are determined with Microsoft EXCEL™. The cumulated activity is calculated using the software ORIGIN PRO 8.1G™ and a mono- or biexponential fit of the time-activity curves. Mean absorbed doses are finally estimated using the software OLINDA EXM™.

Results

We found a compromise between the calculation model and practical conditions. It has ensured dose estimation in daily clinical routine with a reasonable effort and within acceptable time. In consequence, the dosimetry method developed for Bad Berka allows each of our patients to undergo dosimetry after therapy using Lu-177-labeled peptides (peptide receptor radionuclide therapy). Additionally, this approach can be used for any internal radiotherapy using a gamma-emitting radionuclide.

Conclusion

The BBDP is a practicable dosimetric approach, which can be used in daily clinical routine. It not only helps in identifying patients who would benefit most from the treatment, but also those with unfavorable dosimetry. Additionally, the analysis of dosimetric data from peptide receptor radionuclide therapy (PRRNT) could help in predicting possible toxicity.

How to cite this article

Schuchardt C, Kulkarni H, Zachert C, Baum RP. Dosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol—Practical Experience. J Postgrad Med Edu Res 2013;47(1):65-73.


PDF Share
  1. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imag 2011;55(2):155-67.
  2. EANM Dosimetry Committee guidance document: Good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imag 2011;38:192-200.
  3. 3-D imaging based, radiobiological dosimetry. Semin Nucl Med 2008;5:321-34.
  4. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212-25.
  5. MIRD Pamphlet 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.
  6. Dosimetry of internal emitters. J Nucl Med 2005;46:18S-27S.
  7. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85(3):294-310.
  8. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTANOC. Cancer Biother Radiopharm 2007;22(3):406-16.
  9. OLINDA/EXM: The secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-27.
  10. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multi-institutional comparison. J Nucl Med 2004;45:1725-33.
  11. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993;34:669
  12. Dosimetry in nuclear medicine therapy: What are the specifics in image quantification for dosimetry? Q J Nucl Med Mol Imag 2011;55(1):5-20.
  13. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imag 2010;37:212-25.
  14. 177Lu-[DOTA0,Tyr3] Octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010;116(4 Suppl):1084-92.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.